Global Therapeutic Plasma Exchange Market

The global therapeutic plasma exchange market is expected to be worth USD 1,528.40 million in 2021 and USD 2306.60 million by 2028, growing at a CAGR of around 7.10% over the forecast period.

The research investigates the therapeutic plasma exchange market’s drivers, restraints, and challenges, as well as their impact on demand throughout the forecast period. Furthermore, the report looks into new opportunities in the therapeutic plasma exchange market.

Therapeutic Plasma Exchange Market: Overview

Therapeutic plasma exchange (TPE), also known as plasmapheresis, is an endovascular blood treatment that removes toxic substances from patients’ blood and replaces them with replacement fluid such as albumin solution or, more commonly, fresh frozen plasma. These substances include infective autoantibodies, immunological complexes, cryoglobulins, and cholesterol-containing lipoproteins. TPE is used to treat autoimmune diseases, renal disorders, haematological disorders, and other issues, and is expected to drive market growth. Therapeutic plasma exchange has been demonstrated to significantly reduce plasma viscosity (TPE). As a result, it has the potential to increase blood flow and patient outcomes in COVID-19-positive critically ill patients. It is used as a first- or second-line therapy for a variety of chronic disorders in both neurology and non-neurology.

Read Related:

The primary factors driving market growth are an increasing number of clients suffering from inflammatory diseases, haematological disorders, cardiovascular diseases, and the elderly population. The prevalence of neurological health problems among the elderly has increased significantly. The use of cutting-edge techniques in the treatment of neurological illnesses, such as plasma exchange, is also becoming more popular. These factors are expected to drive significant global demand for therapeutic plasma exchange.

Therapeutic Plasma Exchange Market: Segmentation

The global therapeutic plasma exchange market is divided into three segments: end users, disease indications, and regions.

The market is segmented into three areas based on end users: hospitals, specialised clinics, and ambulatory surgical centres. The hospital sector will dominate the global market in 2021. This market is predicted to develop the most rapidly. The hospital sector’s dominance can be ascribed to an increase in patients with autoimmune disorders, as well as individuals who use Medicare and other funding systems.

The global therapeutic plasma exchange market is classified into numerous segments, such as neurological disorders, renal disorders, haematology disorders, and others. In this market, the neurological disorder is predicted to have the biggest market share.

Therapeutic Plasma Exchange Market: Competitive Landscape

Some of the main competitors dominating the global therapeutic plasma exchange market include- Asahi Kasei Corporation, Baxter International, Inc., Terumo Corporation, B. Braun Melungeon AG, Fresenius Kabir AG, Karasumi Laboratories, Inc., Haemon tics Corporation, Ceros Corporation, Hema care Corporation, and Medica S.p.A.

Global Therapeutic Plasma Exchange Market is segmented as follows:

By Diseases Indication

Neurological Disorders

Renal Disorders

Hematology Disorders

By End-Users


Specialty Clinics

Ambulatory Surgical Centers

By Region

North America

The U.S.




The UK




Rest of Europe

Asia Pacific




South Korea

Southeast Asia

Rest of Asia Pacific

Latin America



Rest of Latin America

Middle East & Africa


South Africa

Rest of Middle East & Africa

Contact Us

Zion Market Research

US OFFICE NO +1 (302) 444-0166

US/CAN TOLL-FREE +1 (855) 465-4651

Leave a Reply

Your email address will not be published. Required fields are marked *